Literature DB >> 23080093

IgG, IgM and inflammatory markers serum concentration in patients with acute coronary syndrome: a pilot study.

Lukasz Kołtowski1, Krzysztof J Filipiak, Adam Rdzanek, Violetta Stępień, Bożenna Tarchalska-Kryńska, Grzegorz Opolski.   

Abstract

BACKGROUND: A number of biomarkers have been found that might help to predict the risk of acute coronary syndrome (ACS) in adults. AIM: To analyse the association between immunoglobulins concentration and other inflammatory markers such as C-reactive protein (CRP) and fibrinogen that show correlation with the risk of ACS.
METHODS: The study population consists of 52 consecutive patients with ST segment elevation myocardial infarction (STEMI) or unstable angina/non-STEMI. Concentrations of total protein, albumin, alpha-1 globulin, beta globulin, gamma protein, immunoglobulin in class A (IgA), G (IgG), M (IgM) and E (IgE), creatinine kinase (CK), creatinine kinase MB (CK-MB), CRP and fibrinogen were quantified.
RESULTS: In the ACS patients, there was a significant increase in gamma globulin, CRP and fibrinogen. IgG was elevated only in the STEMI group and correlated with fibrinogen (R = 0.48, p 〈 0.01).
CONCLUSIONS: 1. IgG appears to be the only immunoglobulin associated with ACS in the STEMI group. 2. Fibrinogen reveals features of a reactive biomarker of ACS. 3. CRP appears to be closely related to the causative process in coronary artery disease patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23080093

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  1 in total

1.  Ambient fine particulate air pollution triggers ST-elevation myocardial infarction, but not non-ST elevation myocardial infarction: a case-crossover study.

Authors:  Blake Gardner; Frederick Ling; Philip K Hopke; Mark W Frampton; Mark J Utell; Wojciech Zareba; Scott J Cameron; David Chalupa; Cathleen Kane; Suresh Kulandhaisamy; Michael C Topf; David Q Rich
Journal:  Part Fibre Toxicol       Date:  2014-01-02       Impact factor: 9.400

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.